AIM Rule 17 and Schedule 2(g) Update
Non-Executive Director Martin Gouldstone's company Oncimmune Holdings placed into administration.
Select text to share a quote on X · sign in to keep highlights & notes in your HVO notes
hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces the following update in relation to directors' disclosure for Martin Gouldstone, Non-Executive Director of the Company, pursuant to AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
Oncimmune Holdings plc, a company of which Martin Gouldstone is CEO, was placed into administration on 26 March 2025.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.